Back to School: How biopharma can reboot drug development. Access exclusive analysis here

DPX-Survivac: Additional Phase I/II data

Additional data from the open-label, dose-ranging Phase I/Ib portion of a North American Phase I/II trial in 54 evaluable patients with stage IIc-IV ovarian cancer showed

Read the full 261 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE